Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties

Patent metadata

Field	Value
Publication number	US-9676780-B2
Application number	US-201314655572-A
Country	US
Kind code	B2
Filing date	Dec 20, 2013
Priority date	Dec 20, 2012
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

First claim

What is claimed is:

1. A compound of Formula A, or a pharmaceutically acceptable salt thereof:

wherein:
“m” and “n” are independently an integer of from 1 to 3, with the proviso that no more than two R G2a substituents are located on adjacent ring carbon atoms;
R G2a is independently: (i) —OH; (ii) —CN; (iii) Halogen; (iv) —C 1-6 -linear alkyl, optionally substituted by one or more fluorine atoms; or (v) —C 1-6 -alkoxy, optionally substituted by a C 1-4 -alkoxy moiety;
R G4 and R G5 are:
(a) independently, for each occurrence, (i) —H; (ii) —F; or (iii) —C 1-6 -alkyl which is optionally substituted with one or more fluorine substituents; or
(b) R G4 and R G5 are taken together to form a carbonyl [—C(O)—] moiety, with the proviso that where “m”>1, R G4 and R G5 are not selected to form two adjacent carbonyl moieties; and

M G1 is a moiety of the formula:

wherein:
R a1 , R a2 , R a3 , R a4 , R a5 , and R a6 , are defined as follows:
(a) R a6 is: —H; or —CH 3 ; and R a1 ; R a2 ; R a3 ; R a4 ; and R a5 are independently:
(i) —H;
(ii) an aromatic moiety of from 6 to 10 carbon atoms; or
(iii) —C 1-5 linear, branched or cyclic alkyl which is optionally substituted with one or more of —F or —C 1-4 -alkyl substituent wherein one or more carbon atoms in said optional C 1-4 -alkyl substituent are optionally substituted with one or more —F atoms; or

(b) R a1 , R a2 , R a3 , and R a4 are independently: —H, —C 1-5 linear, —C 3-5 -branched or —C 3-5 -cyclic alkyl; and R a5 and R a6 together form a bridge of the formula: —(CH 2 ) q —, thereby providing a moiety of the structure:

 where “q” is 1 or 2;
(c) one pair of R a1 /R a2 or R a3 /R a4 together form an oxo-functional group and the other pair are hydrogen, providing a structure of Formula Ga 1 or Ga 2 :

(d) one pair of R a1 /R a2 or R a3 /R a4 are each —H and the other pair together comprise up to five carbon atoms which are cyclized to form a spirocyclo moiety of Formula Fb 3 or Formula Fb 4 :

wherein “p” is an integer from 1 to 3; or

(e) R a1 , R a2 , R a3 , R a4 , R a5 , and R a6 are selected to provide an ethylene-bridged moiety of the formula:

wherein: (i) R a6 together with one of R a3 or R a4 form an ethylene bridge and any of R a1 , R a2 , R a3 , R a4 , or R a5 , which are not part of said ethylene bridge are hydrogen; (ii) R a5 together with one of R a1 or R a2 form an ethylene bridge and any of R a1 , R a2 , R a3 , R a4 , or R a6 which are not part of said ethylene bridge are hydrogen; or (iii) R a6 together with one of R a3 or R a4 , and R a5 together with one of R a1 or R a2 each form ethylene bridge, and any of R a1 , R a2 , R a3 , or R a4 which are not selected to form an ethylene bridge are hydrogen; and

R b2 is:
(a) C 1-6 -linear, C 3-6 -branched, or C 3-6 -cyclic-alkyl, which alkyl moiety is optionally substituted with one or more substituents which are, independently: (i) halogen; (ii) C 1-6 -alkoxy; or (iii) C 1-6 -alkyl-SO 2 —;
(b) —C(O)—R c1 wherein, “R c1 ” is: (i) aryl; (ii) C 1-6 -alkoxy; or (iii) C 1-6 -linear, C 3-6 -branched, or C 3-6 -cyclic-alkyl;
(c) a mono- or polycyclic aryl moiety comprising from 5 to 10 carbon atoms which is optionally linked to a nitrogen of the piperazine moiety through a carbonyl carbon, thereby forming an amide linkage, and wherein the ring of said aryl moiety optionally comprises one or more substituents which are, independently:
(i) halogen;
(ii) C 1-6 -alkyl, optionally halogen substituted;
(iii) C 1-6 -alkoxy;
(iv) C 1-6 -alkoxy-C 1-6 -alkoxide;
(v) aryloxy of from 6 to 10 carbon atoms;
(vi) C 1-6 -heterocycloalkyl comprising from 1 to 3 heteroatoms which are, independently for each occurrence “N”, “S”, or “O”, wherein said heterocycl-ring may optionally include a carbonyl group (C═O);
(vii) (R d1 ) 2 N—, wherein “R d1 ” is independently —H or —C 1-6 -alkyl;
(viii) nitrile;
(ix) mono- or polycyclic heteroaryl of from 5 to 10 carbon atoms, comprising from 1 to 4 heteroatoms which are, independently for each occurrence, “N”, “O”, or “S”; or
(x) —C(O)—OH; or

(d) a mono- or polycyclic heteroaryl moiety comprising from 5 to 10 carbon atoms and from 1 to 4 heteroatoms which are independently for each occurrence, “N”, “O”, or “S”, which is optionally linked to a nitrogen of the piperazine moiety through a carbonyl carbon, thereby forming an amide linkage, and wherein, optionally one or more ring carbon atoms is substituted with a moiety which is, independently for each occurrence:
(i) —halogen;
(ii) —C 1-6 -alkyl-sulfonyl;
(iii) —C 1-6 -alkyl which is optionally substituted with one or more substituents that are, independently for each occurrence, halogen or C 1-6 -alkoxide;
(iv) —C 1-6 -alkoxide which is optionally substituted with one or more substituents that are, independently for each occurrence, halogen or —C 1-6 -alkyl;
(v) C 1-6 —C(O)—;
(vi) —CN; or
(vii) C 1-6 C(O)O—.

2. A compound of Formula A, or a pharmaceutically acceptable salt thereof, having the structure of Formula AI:

wherein:
“n”, M G1 , R G4 and R G5 are as defined for the compound of Formula A;
R G2 is independently:
(i) —OH;
(ii) —CN;
(iii) Halogen;
(iv) —C 1-3 -linear alkyl which is optionally substituted by one or more fluorine substituents; or
(v) —C 1-6 -alkoxy, which is optionally substituted by a C 1-4 -alkoxy moiety; and

R G3 is —H or —F.

3. A compound of claim 1 having the Formula CC1:

CC1, or a salt thereof,
wherein R c16 is:

4. The compound of claim 1 having the Formula CC2:

or a salt thereof,
wherein R d is:

5. The compound of claim 1 having the Formula CC3:

or a salt thereof,
wherein R a1 to R a4 and R b2 are each defined in Table CTI.

TABLE CTI

R a1 /R a2
R a3 /R a4
R b2

Assignees

• Merck Sharp & Dohme
• Ali Amjad
• Lo Michael Man-Chu
• Lim Yeon-Hee
• Stamford Andrew
• Kuang Rongze
• Tempest Paul
• Yu Younong
• Berlin Michael
• Ting Pauline
• Zhou Gang
• Yu Tao
• Boyce Christopher
• Kelly Joseph Michael
• Tagat Jayaram R
• Zheng Junying
• Huang Xianhai
• Zhou Wei
• Kim Jae-Hun
• Zorn Nicolas
• Xiao Dong
• Gallo Gioconda V
• Won Walter
• Wu Heping
• Anand Rajan
• Deng Qiaolin

Inventors

• Ali Amjad
• Lo Michael Man-Chu
• Lim Yeon-Hee
• Stamford Andrew
• Kuang Rongze
• Tempest Paul
• Yu Younong
• Berlin Michael
• Ting Pauline
• Zhou Gang
• Yu Tao
• Boyce Christopher
• Kelly Joseph Michael
• Tagat Jayaram R
• Zheng Junying
• Huang Xianhai
• Zhou Wei
• Kim Jae-Hun
• Zorn Nicolas
• Xiao Dong
• Gallo Gioconda V
• Won Walter
• Wu Heping
• Anand Rajan
• Deng Qiaolin

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• C07D513/04

  Ortho-condensed systems · CPC title

• C07D487/18

  Bridged systems · CPC title